Medical technology company Qlife's interim report for the third quarter of 2025 devotes great focus to the planned merger with Chinese Hipro Biotechnology. At the same time, the company has taken important steps in product development and regulatory processes, including the proprietary self-test Egoo PHE for phenylketonuria (PKU).
Read the full article at biostock.se:
Qlife remains focused on planned merger with Chinese Hipro
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
© Modular Finance, source Nordic Press Releases